Grounded in peer-reviewed science.
Each biomarker stream rests on published research, not internal claims. The platform is co-developed with senior academic neurologists and validated in hospitals.
Four signals, each with a published basis.
Voice & speech analysis
Validated across more than ten peer-reviewed studies as a marker of neurocognitive change.
Winterlight Labs; Nature Digital Medicine (2022).
Eye tracking / saccadics
An established Alzheimer's and Parkinson's biomarker in the published literature.
EAN-validated; WHO-approved assessment tools.
Neurocognitive performance
Built on international gold-standard instruments scored for reaction time and accuracy.
MoCA, Trail Making, Stroop; WHO-approved.
Facial expression detection
Validated for early dementia and neurocognitive-disorder diagnostics, captured non-invasively via the smartphone camera.
Published micro and macro-expression literature.
A 3.000-patient trial, designed for regulatory weight.
The trial design is built so that one study supports the full EU regulatory file. This describes the trial design and is an objective, not a completed result.
Three groups
Healthy controls (45 to 65); MCI / early Alzheimer's risk; early Parkinson's risk.
Academic centres
We work with several academic institutions.
18 + 6 months
Eighteen months of data collection plus a six-month follow-up period.
Pre-registration
Planned pre-registration on ClinicalTrials.gov; one trial supports the full EU regulatory file.
Validated with hospitals and academic centres.
Deep Medicine is being developed with the help of several clinical and academic partners. If your organisation is interested in joining, contact us.
Advisory board
Announced soon.